Discovery of highly potent, selective, orally bioavailable, metabotropic glutamate subtype 5 (mGlu5) receptor antagonists devoid of cytochrome P450 1A2 inhibitory activity.

Structure-activity relationship studies focused on bio-isosteric replacements of 2-pyridyl resulted in mGlu5 receptor antagonists with reduced inhibition of cytochrome P450 1A2. This led to highly potent, selective and orally bioavailable 2-imidazolyl tetrazoles such as (10) that are devoid of cytochrome P450 inhibitory activity.

[1]  W. Spooren,et al.  Pharmacological and endocrinological characterisation of stress-induced hyperthermia in singly housed mice using classical and candidate anxiolytics (LY314582, MPEP and NKP608). , 2002, European journal of pharmacology.

[2]  M. Koch,et al.  The metabotropic glutamate receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) blocks fear conditioning in rats , 2001, Neuropharmacology.

[3]  Mark Washburn,et al.  3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. , 2003, Journal of medicinal chemistry.

[4]  Andrzej Pilc,et al.  Anxiolytic-like effects of group I metabotropic glutamate antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) in rats. , 2000, Polish journal of pharmacology.

[5]  J. Pin,et al.  Pharmacology and functions of metabotropic glutamate receptors. , 1997, Annual review of pharmacology and toxicology.

[6]  F. Conquet,et al.  Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice , 2001, Nature Neuroscience.

[7]  N. Cosford,et al.  In vivo receptor occupancy of mGlu5 receptor antagonists using the novel radioligand [3H]3-methoxy-5-(pyridin-2-ylethynyl)pyridine). , 2003, European journal of pharmacology.

[8]  R. Gereau,et al.  Metabotropic glutamate receptor involvement in models of acute and persistent pain: prospects for the development of novel analgesics. , 2002, Current drug targets. CNS and neurological disorders.

[9]  Jesse Brodkin,et al.  Anxiolytic-like activity of the mGluR5 antagonist MPEP A comparison with diazepam and buspirone , 2002, Pharmacology Biochemistry and Behavior.

[10]  K. Kondo,et al.  A NEW SYNTHESIS OF 2,5-DISUBSTITUTED TETRAZOLES VIA 1,5-DIPOLAR CYCLIZATION , 1973 .

[11]  N. Cosford,et al.  [3H]-methoxymethyl-MTEP and [3H]-methoxy-PEPy: potent and selective radioligands for the metabotropic glutamate subtype 5 (mGlu5) receptor. , 2003, Bioorganic & medicinal chemistry letters.

[12]  N. Cosford,et al.  Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity. , 2004, Journal of medicinal chemistry.

[13]  A. Young,et al.  Molecular and functional characterization of recombinant human metabotropic glutamate receptor subtype 5 , 1995, Neuropharmacology.

[14]  F. Gasparini,et al.  Potential anxiolytic‐ and antidepressant‐like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist , 2001, British journal of pharmacology.

[15]  W. Spooren,et al.  Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. , 2000, The Journal of pharmacology and experimental therapeutics.

[16]  Y. Matsue,et al.  Highly polarized tropones. 9H-Azuleno(1,2,3-ij)naphthalen-9-one and 8H-azuleno(1,2,3-ij)naphthalen-8-one. , 1981 .

[17]  C. King,et al.  Inhibition of human hepatic CYP isoforms by mGluR5 antagonists. , 2004, Life sciences.